On Tuesday, Degroof Petercam renewed its buy recommendation on Carmat shares, with an unchanged target price of 20.5 euros.

In a note published this morning, the financial intermediary believes that yesterday's business update from the medical device company testifies to a "sustained acceleration in its development prospects".

Overall, the information provided by the company is particularly encouraging and shows that surgeons have high hopes for its artificial heart", adds the analyst.

The sales target of 10 to 13 million euros provided this year, followed by the achievement of profitability by 2027, are also in line with its estimates, it points out in its note.

Degroof Petercam adds, however, that it plans to revise its model to take account of the company's new forecasts in terms of business acceleration.

Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as decision-making aids for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.